Assessing risk and progression of pre-diabetes and type 2 diabetes to enable disease modification

The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment.

Our plans are built upon:
  • access to large European cohorts with comprehensive genetic analyses, rich longitudinal clinical, biochemical data and samples
  • detailed multi-omic maps of key T2D-relevant tissues and organs
  • large expertise in the development and use of novel genetic, epigenetic, biochemical and physiological experimental approaches
  • the ability to combine existing and novel data sets through effective data federation and use of these datasets in systems biology approaches towards precision medicine;
  • expertise in regulatory approval, health economics and patient engagement.

These activities will lead to the discovery of novel biomarkers for improved T2D taxonomy, to support development of pharmaceutical activities, and for use in precision medicine to improve health in Europe and worldwide.

Latest news

Database on Funding Activities for Personalised Medicine (PM) Research Has Been Launched

The International Consortium for Personalised Medicine (ICPerMed) database, launched on 5 July 2018, gives an overview on the actions in the
» Read more

PhD positions in Co-Fund project on Personalized medicine in chronic diseases with a focus on diabetes

The University Medical Center Groningen, the Netherlands, is about to start a H2020 supported Co-Fund project on Personalized medicine in
» Read more

Innovative Medicines Initiative: Publication of IMI1 and IMI2 evaluations

The Innovative Medicines Initiative has just published the final review of the IMI1 programme, and the mid-term review of IMI2.The experts
» Read more
Stacks Image p6767_n47
Stacks Image p6767_n398
Stacks Image p6767_n51
Stacks Image p6767_n349
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115881. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097-2.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.